Summary
Animal experiments have shown that the administration of calcium antagonists can prevent or slow the progression of atherosclerosis by inhibiting calcium overload and interfering with lipid metabolism and deposition. These encouraging results have prompted clinical trials to evaluate the effects of calcium antagonists (dihydropyridines and diphenylalkylamines) on atherosclerotic plaque formation. In patients with coronary heart disease, several studies have already shown that calcium antagonists can have a positive effect on plaque evolution, while in hypertensive patients no such study has been published to date.
The Verapamil in Hypertension Atherosclerosis Study is an ongoing multicentre randomised double-blind parallel group trial comparing the antihypertensive efficacy of verapamil SR 240 mg/day with that of chlorthalidone 25 mg/day in 1464 patients with essential hypertension aged 40 to 65 years. In a randomised subgroup of patients (n = 550), who will be followed up for 3 years, B-mode ultrasonography is being employed to evaluate the effects of the 2 drugs on carotid wall thickness and carotid plaque development. Ultrasonographic evaluations are performed at baseline, after 3 months, and 1, 2 and 3 years after a standardised protocol to determine intimal-medial thickness in 4 segments of the extracranial carotid tree.
The most interesting result to date is the high incidence of carotid alterations, with plaques present in 35% and arterial wall thickening in 31.8% of the 311 asymptomatic hypertensive patients processed so far. A preliminary evaluation of the antihypertensive efficacy of the trial medications after 6 months of double-blind treatment indicates a 63.5% response rate to monotherapy and a 7.8% drop-out rate because of drug inefficacy or intolerance.
Similar content being viewed by others
References
Bond MG, Strickland HL, Wilmoth SK, Safrit A, Phillips R, et al. for the MIDAS Research Group. Interventional clinical trial using noninvasive ultrasound endpoints: the Multicenter Isradipine/Diuretic Atherosclerosis Study. Journal of Cardiovascular Pharmacology 15(Suppl. 1): S30–S33, 1990
Borhani ON, Brugger SB, Byngton RP for the US MIDAS Research Group. Multicenter study with isradipine and diuretics against atherosclerosis. Journal of Cardiovascular Pharmacology 15(Suppl. 1): S23–S29, 1990
Dupuis BA. Antagonistes de calcium en vieillissement vasculaire. Annales de Cardiologie et d’Angeiologie 40: 359–362, 1991
HDEP Cooperative Group. Five-years findings of the Hypertension Detection Follow-up Program. III Reduction in stroke incidence among persons with high blood pressure. Journal of the American Medical Association 247: 633–638, 1982
Henry PD. Anti-atherogenic effects of calcium channel blockers: possible mechanisms of action. Cardiovascular Drugs Therapy 4(Suppl. 5): 1015–1020, 1990
Kannel WB. Hypertension: relationship with other risk factors. Drugs 31(Suppl. 1): 1–11, 1986
Kober G, Schneider W, Kaltenbach M. Can the progression of coronary sclerosis be influenced by calcium antagonists? Journal of Cardiovascular Pharmacology 13(Suppl. 4): S2–S6, 1990
Lichtlen PR, Hugenholtz PG, Rafflenbeul W, Hecker H, Jost S, et al. for the INTACT Group Investigators. Retardation of angiographic progression of coronary artery disease by nifedipine. Lancet 335: 1109–1113, 1990
MacMahon SW, Cutler JA, Neaton JD, Furberg CD, Cohen JD, et al. Relationship of blood pressure to coronary and stroke morbidity and mortality in clinical trials and in epidemiological studies. Journal of Hypertension 4(Suppl. 6): S14–S17, 1986
Parmley WW. Vascular protection from atherosclerosis: potential of calcium antagonists. American Journal of Cardiology 66: 161–221, 1990
Ram SVC. Antiatherosclerotic and vasculoprotective actions of calcium antagonists. American Journal of Cardiology 66: 291–321, 1990
Waters D, Lesperance J, Francetich M, Causey D, Theroux P, et al. A controlled clinical trial to assess the effects of a calcium channel blocker on the progression of coronary atherosclerosis. Circulation 82: 1940–1953, 1990
Weinstein DB, Heider JG. Antiatherogenic properties of calcium antagonists. American Journal of Cardiology 59: 163B–172B, 1987
Author information
Authors and Affiliations
Consortia
Rights and permissions
About this article
Cite this article
Magnani, B., Palù, C.D., Zanchetti, A. et al. Preliminary Clinical Experience with Calcium Antagonists in Atherosclerosis. Drugs 44 (Suppl 1), 128–133 (1992). https://doi.org/10.2165/00003495-199200441-00024
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-199200441-00024